Business
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024 CAMBRIDGE,
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024\nCAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today announced it has terminated its previously established \"at-the-market\" (\"ATM\") equity offering program. The termination will take effect at the close of business on October 4th, 2023, following the 3-day termination process of the ATM offering \n\n\"Having completed enrollment in our Phase 2b ALS trial in the second quarter, we continue to dose and monitor patients for the 6-month double blind portion of the study. We also expect to enroll our first patient in our new Phase 2 Alzheimer's disease study in the coming weeks. With clarity on our R&D and operating expenses, we are confident that our Company is fully funded into the second quarter of 2024,\" stated NeuroSense Founder and CEO, Alon Ben-Noon. \"With our extensive use of biomarkers in the Phase 2b study, we are optimistic about PrimeC's mechanism of action and its corresponding clinical results anticipated in Q4 2023.\"\nAbout NeuroSense\nNeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.\nFor additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.\nForward-Looking Statements\nThis press release contains \"forward-looking statements\" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statem...